JPRN-UMIN000037123尚未招募未知
Evaluation of the efficacy and safety of romosozumab alone and romosozumab + denosumab combination for patients with osteoporosis treated with 2-year denosumab - Evaluation of the efficacy and safety of romosozumab alone and romosozumab + denosumab combination for patients with osteoporosis treated with 2-year denosumab
Shinshu University School of Medicine Dept. of Orthopaedic Surgery0 个研究点目标入组 60 人开始时间: 2019年6月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1:Patients who have taken romosozumab or denosumab before 2:Patients who are allergic to romosozumab or denosumab or eldecalcitol 3:Hypocalcemia 4:Pregnant or breast-feeding patients 5:Patients with severe renal function (eGFR 30 ml / min / 1.73 m2) or patients undergoing dialysis 6:Patients at risk of hypercalcemia (patients with renal dysfunction, patients with malignancy, patients with primary hyperparathyroidism) 7:Patients with severe liver dysfunction 8:Patients with urolithiasis and patients with a history of their history
研究者
相似试验
招募中
不适用
Evaluation of efficacy and safety of romosozumab administration group and ibandronate sodium hydrate administration group for osteoporosis patients after denosumab treatmentosteoporosisJPRN-UMIN000037394Shinshu University School of Medicine Dept. of Orthopaedic Surgery60
招募中
不适用
Examination of efficacy and safety treated by romosozumab or denosumab in osteoporosis with collagen disease including glucocorticoid-induced osteoporosisosteoporosis with collagen disease including glucocorticoid-induced osteoporosisJPRN-UMIN000036837Shinshu University School of Medicine Dept. of Orthopaedic Surgery60
未知
4 期
A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Long-Term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease as Measured by Intravascular UltrasonographyHypercholesteremiaJPRN-jRCT1080220348AstraZeneca/Shionogi
招募中
2 期
Romiplostim in treatment-naïve acquired aplastic anemiaIRCT20221129056655N2Shiraz University of Medical Sciences23
招募中
2 期
Romiplostim in treatment-refractory acquired aplastic anemiaIRCT20221129056655N1Shiraz University of Medical Sciences24